SRES-464-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S7735; text: CR S7732-7733)
Sponsored by Cindy Hyde-Smith (R-MS)
What it does
This Senate resolution designates September 2025 as "National Cholesterol Education Month" and September 30, 2025, as "LDL-C Awareness Day." It encourages all Americans to learn their low-density lipoprotein cholesterol (LDL-C) number and recognizes the need for screening and treatment of elevated LDL-C to reduce cardiovascular disease risk. The resolution carries no legal mandates, appropriations, or regulatory requirements.
Who benefits
The general public, particularly the more than 25.5% of U.S. adults with high LDL-C, may benefit from increased awareness. Cardiovascular disease patients, especially those in rural areas and African-American communities identified in the resolution as underserved, could benefit from heightened attention to screening gaps. Healthcare providers, patient advocacy organizations, and pharmaceutical companies that manufacture cholesterol-lowering therapies may benefit from increased public attention to the issue.
Who is hurt
No group faces a direct material harm from a purely commemorative resolution. Indirectly, competing public health awareness campaigns may receive less attention during September if cholesterol education is elevated. There are no regulatory burdens, costs, or restrictions imposed on any party.
Supporters argue
Supporters argue that cardiovascular disease is the leading cause of death in the United States and that awareness gaps are measurable and consequential — only 27% of heart attack patients receive a recommended LDL-C follow-up test within 90 days of discharge, and 71% of high-risk hypercholesterolemia patients never reach recommended treatment thresholds. They contend that a nationally designated awareness period can prompt individuals, clinicians, and health systems to close these documented gaps at no federal cost.
Opponents argue
Opponents argue that commemorative resolutions consume legislative time without creating enforceable change, and that the documented gaps in LDL-C screening and treatment — particularly among African-American patients and rural populations — require substantive policy action such as funding, coverage mandates, or provider incentives rather than symbolic designation. They contend that without accompanying legislation or appropriations, the resolution is unlikely to materially affect the care disparities it identifies.